Regeneron Pharmaceuticals has announced a new manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies to enhance its production capacity for biologic medicines at Fujifilm's facility ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the ...

FUJIFILM Diosynth Biotechnologies signed a 10-year manufacturing supply agreement, valued at over $3 billion, with Regeneron Pharmaceuticals to provide U.S.-based production of its biologic medicines.

Regeneron Pharmaceuticals stock crashed Monday after its experimental melanoma treatment failed in Phase 3 testing.

A $125 million near-term package comprises $50 million upfront and a $75 million equity commitment, with total potential value up to $2.325 billion including milestones and tiered low–double-digit ...

Contract manufacturer FujiFilm Diosynth Biotechnologies, which has been expanding its footprint in Holly Springs, has signed a $3 billion agreement to make treatments for Regeneron Pharmaceuticals.

Switzerland-based Roche said it will spend $50B in the U.S. over the next five years and create 12,000 jobs. The investment will fund research and development facilities as well as new manufacturing ...

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon™ peptide platform Agreement provides for Parabilis to receive $125M from ...